NZ618331A - Stable formulations of a hyaluronan-degrading enzyme - Google Patents

Stable formulations of a hyaluronan-degrading enzyme

Info

Publication number
NZ618331A
NZ618331A NZ618331A NZ61833112A NZ618331A NZ 618331 A NZ618331 A NZ 618331A NZ 618331 A NZ618331 A NZ 618331A NZ 61833112 A NZ61833112 A NZ 61833112A NZ 618331 A NZ618331 A NZ 618331A
Authority
NZ
New Zealand
Prior art keywords
hyaluronan
degrading enzyme
stable formulations
composition
stable
Prior art date
Application number
NZ618331A
Other languages
English (en)
Inventor
Daniel Edward Vaughn
Tzung-Horng Yang
Michael James Labarre
Christopher L Caster
Francois Nicol
Donghyun Kim
Original Assignee
Halozyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halozyme Inc filed Critical Halozyme Inc
Priority to NZ717728A priority Critical patent/NZ717728A/en
Publication of NZ618331A publication Critical patent/NZ618331A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ618331A 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme NZ618331A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ717728A NZ717728A (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161520962P 2011-06-17 2011-06-17
PCT/US2012/042816 WO2012174478A2 (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Publications (1)

Publication Number Publication Date
NZ618331A true NZ618331A (en) 2016-04-29

Family

ID=46513830

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ618331A NZ618331A (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme
NZ717728A NZ717728A (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ717728A NZ717728A (en) 2011-06-17 2012-06-15 Stable formulations of a hyaluronan-degrading enzyme

Country Status (13)

Country Link
EP (1) EP2720712B1 (enExample)
JP (3) JP2014518216A (enExample)
KR (2) KR20140043438A (enExample)
CN (2) CN103974715A (enExample)
AU (2) AU2012271359B2 (enExample)
BR (1) BR112013032396A2 (enExample)
CA (1) CA2839511C (enExample)
EA (2) EA201400031A1 (enExample)
ES (1) ES2566549T3 (enExample)
IL (1) IL229749A0 (enExample)
MX (1) MX340172B (enExample)
NZ (2) NZ618331A (enExample)
WO (1) WO2012174478A2 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12011502708B1 (en) 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
PT2950780T (pt) * 2013-02-04 2020-07-07 Sanofi Sa Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
TW201605489A (zh) * 2013-10-25 2016-02-16 賽諾菲公司 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
JP6562902B2 (ja) * 2014-03-28 2019-08-21 テルモ株式会社 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN104095871A (zh) * 2014-07-10 2014-10-15 青岛蔚蓝生物股份有限公司 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液
WO2016011262A1 (en) 2014-07-16 2016-01-21 New York University Use of hyaluronidase for treatment of muscle stiffness
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN105018457A (zh) * 2015-07-20 2015-11-04 宁波美成生物科技有限公司 虫荧光素酶稳定剂
US20190382439A1 (en) * 2015-11-16 2019-12-19 Ubiprotein, Corp. Method for extending half-life of a protein
CN107789373A (zh) * 2016-09-06 2018-03-13 杏辉天力（杭州）药业有限公司 茯苓萃取物及其活性成分于保养肌肤及／或促进伤口愈合的用途
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
CN108070532A (zh) * 2016-11-16 2018-05-25 福建力多利生物科技有限公司 一种生产葡萄糖氧化酶的方法
WO2019050749A1 (en) 2017-09-08 2019-03-14 Eli Lilly And Company PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL
CN107918020B (zh) * 2017-11-15 2019-01-01 浙江夸克生物科技有限公司 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
CN112203642B (zh) 2019-03-25 2025-03-07 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
CN110592056A (zh) * 2019-09-19 2019-12-20 昆明理工大学 噬菌体裂解酶复合粉剂及其制备方法和应用
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
TW202615652A (zh) * 2020-01-23 2026-04-16 南韓商阿特根公司 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物
WO2022031093A1 (ko) 2020-08-07 2022-02-10 (주)알테오젠 재조합 히알루로니다제의 생산 방법
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
PT4267105T (pt) 2020-12-28 2025-04-30 Bristol Myers Squibb Co Composições de anticorpos e métodos de utilização das mesmas
WO2022141232A1 (zh) * 2020-12-30 2022-07-07 上海宝济药业有限公司 一种重组人透明质酸酶制剂及其应用
CA3236277A1 (en) * 2021-10-29 2023-05-04 Soon Jae Park Pharmaceutical composition comprising human hyaluronidase ph20 and drug
CN115820766B (zh) * 2021-12-28 2024-11-12 华熙生物科技股份有限公司 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4640210A1 (en) * 2022-12-23 2025-10-29 Hanmi Pharm. Co., Ltd. Formulation containing immunoactive interleukin 2 analog conjugate
KR102554775B1 (ko) * 2023-02-07 2023-07-12 한국코러스 주식회사 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형
CN117243852B (zh) * 2023-11-01 2026-05-19 华熙生物科技股份有限公司 一种皮肤外用组合物及其用途
CN117866931B (zh) * 2024-01-09 2026-08-07 江南大学 一种胞外分泌表达的透明质酸裂解酶及其重组菌与应用
CN119074669B (zh) * 2024-06-21 2025-04-18 邢珺月 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0162007A1 (de) * 1984-04-18 1985-11-21 Geriaco AG Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris
EP0250119A3 (en) * 1986-06-20 1990-04-18 Vasocor Atherosclerotic anti-idiotype antibody immunoassay and reagents
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US6093563A (en) 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5747027A (en) 1995-04-07 1998-05-05 The Regents Of The University Of California BH55 hyaluronidase
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6610292B2 (en) * 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6669663B1 (en) * 1999-04-30 2003-12-30 Medtronic, Inc. Closed loop medicament pump
US6559363B1 (en) * 1999-07-05 2003-05-06 Toyo Boseki Kabushiki Kaisha Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants
CA2394980C (en) 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
ATE330938T1 (de) * 2000-05-19 2006-07-15 Alcon Inc Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen
US6902548B1 (en) * 2001-03-19 2005-06-07 Ed Schuler Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments
US20030125234A1 (en) * 2001-12-11 2003-07-03 Middaugh Charles Russell Alteration of protein stability
EP1596887B1 (en) 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP2330213A1 (en) 2003-03-05 2011-06-08 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
NZ542729A (en) * 2003-04-23 2009-04-30 Hexima Ltd Isolation of a chymotrypsin, HpCh5, from Helicoveipa spp, characterised by its resistance to the proteinase inhibitors derived from Nicotiana alata
EP2106790B1 (en) 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
WO2005095625A1 (en) * 2004-03-31 2005-10-13 Hexima Ltd Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence
WO2005118799A1 (en) * 2004-04-15 2005-12-15 Ista Pharmaceuticals, Inc. Ovine hyaluronidase
WO2007047242A2 (en) * 2005-10-14 2007-04-26 Soll David B Ophthalmic surgical irrigating solutions containing hyaluronidase
WO2007047948A2 (en) * 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
AU2007281433A1 (en) * 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
IL186598A0 (en) 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
CN101970650B (zh) 2008-03-06 2017-07-25 哈洛齐梅公司 可溶性透明质酸酶的大规模生产
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN102307993B (zh) 2008-12-09 2014-06-25 哈洛齐梅公司 延长的可溶性ph20多肽及其用途
PH12011502708B1 (en) * 2009-07-06 2017-11-10 Sanofi Aventis Deutschland Insulin preparations containing methionine
PT2477603E (pt) 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
US20130022592A1 (en) * 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
SG11201403714TA (en) * 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof

Also Published As

Publication number Publication date
CN105797140A (zh) 2016-07-27
MX340172B (es) 2016-06-28
JP2017036313A (ja) 2017-02-16
CN103974715A (zh) 2014-08-06
AU2016202472B2 (en) 2017-02-02
BR112013032396A2 (pt) 2016-11-22
AU2012271359B2 (en) 2016-05-19
CN105797140B (zh) 2020-08-11
JP6224802B2 (ja) 2017-11-01
KR20140043438A (ko) 2014-04-09
WO2012174478A3 (en) 2013-04-11
EA201501068A1 (ru) 2016-07-29
JP2014518216A (ja) 2014-07-28
NZ717728A (en) 2016-04-29
EP2720712A2 (en) 2014-04-23
IL229749A0 (en) 2014-01-30
KR101874401B1 (ko) 2018-07-04
JP2017197556A (ja) 2017-11-02
CA2839511C (en) 2018-07-31
MX2013014923A (es) 2014-02-11
WO2012174478A2 (en) 2012-12-20
EA201400031A1 (ru) 2014-07-30
KR20170116173A (ko) 2017-10-18
EA033472B1 (ru) 2019-10-31
WO2012174478A9 (en) 2013-05-30
CA2839511A1 (en) 2012-12-20
AU2012271359A1 (en) 2014-01-09
EP2720712B1 (en) 2016-03-02
ES2566549T3 (es) 2016-04-13

Similar Documents

Publication Publication Date Title
PE20141384A1 (es) Composiciones de insulina de accion superrapida
BR112013032396A2 (pt) formulações estáveis de aplicações relacionadas à enzima de degradação de ácido hialurônico
MX2012002308A (es) Composiciones plaguicidas espumosas y metodos de aplicacion.
NZ742943A (en) Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex i or ii
MX2014000064A (es) Composicion detergente liquido.
EP2349279A4 (en) MODIFIERS OF ALDEHYDE DEHYDROGENASE AND METHODS OF USE THEREOF
MX2009011823A (es) Piridonacarboxamidas, agentes protectores de plantas utiles que contienen a estas y procedimientos para su preparacion y su utilizacion.
MX336114B (es) Produccion, formulacion, y usos de formulaciones liquidas estables de proteina harpin.
EP3666076A3 (en) Agricultural pesticide compositions
MX2016013575A (es) Composicion para prevenir o tratar enfermedades del higado graso.
NZ597206A (en) Control agent for soft rot and control method for the same
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
NZ733952A (en) Acid composition based on leonardite and amino acids
MX2019010101A (es) Composiciones y metodos para promover el crecimiento del cabello con inhibidores de mpc1.
EP4606435A3 (en) Pharmaceutical composition comprising poorly soluble basic agent
PH12016500222A1 (en) Compounds and methods for improving plant performance
MY162731A (en) Use of chelating agent and peptide antimicrobial compounds
EP2557938A4 (en) PROTECTED ALPHA AMYLASE
MY152388A (en) Composition and method for controlling plant diseases
GEP201706717B (en) Fibrinolytic compositions comprising bromelain and nattokinase for prevention and treatment of phlebothrombtic states
UA101417C2 (ru) Композиции для борьбы с вредителями растений и метод борьбы с вредителями растений
MY159020A (en) Composition and method for controlling plant diseases
BR112015012064A2 (pt) método para tratar um material de tabaco, material de tabaco, artigo para fumo, uso de uma combinação de enzimas protease com condições operacionais ideais diferentes
PH12012501194A1 (en) Composition and method for controlling plant diseases
MX2019014815A (es) Composicion antimicrobiana que incluye un acido dihidroxamico y metodos de inhibicion del crecimiento microbiano que usan el mismo.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUN 2019 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD

Effective date: 20160803

LAPS Patent lapsed